Collin Arocho
28 October

Plasmacure and its cold plasma wound treatment system Plasoma may soon be coming to a hospital near you. The Eindhoven-based medtech developer just announced that it has received a boost in funding to help carry out clinical studies and to sell its solution to hospitals throughout Europe. The injection of capital comes from a consortium of investors, including repeat investors Topfonds Gelderland (managed by Oost NL) and Nextgen Ventures, along with the EU’s EIC Fund and others.

Plasmacure Plasoma
Credit: Plasmacure

The Plasoma system works by attaching a flexible cold plasma pad over a wound. By the push of a button on the connected pulser, energy is delivered to the pad to produce cold plasma at the site of the wound, creating a cocktail of reactive species such as ozone, nitrogen oxides and hydrogenperoxide, which are very effective in killing bacteria and stimulating cell proliferation and microcirculation in the wound. Treatment sessions last only two minutes and can be repeated regularly until the wound has healed. Currently, the Plasoma pad has an active cold plasma area with a diameter of three centimeters, which fits most of the diabetic foot ulcers and open leg wounds, but the company is busy with developing pads in other sizes to fit other wounds.

“Every 30 seconds, someone, somewhere in the world loses a foot through amputation. More than 80 percent of these amputations are caused by diabetic foot wounds that do not heal,” says Bas Zeper, CEO and founder of Plasmacure. “We envision a world where people no longer suffer from chronic wounds. The first results with Plasoma are impressive: 60 percent of wounds have healed.”